Most people do NOT need an RSV vaccine in 2025, but it is recommended for specific higher‑risk groups like older adults and certain people with chronic conditions, and there are also new options to protect infants. Anyone thinking about the RSV shot should confirm with a healthcare professional, because recommendations in 2025 depend a lot on age, health status, pregnancy, and infant risk.

Who should get an RSV vaccine 2025?

For 2025, expert guidance focuses on preventing severe RSV illness and hospitalization, not on vaccinating the entire population. The main groups recommended or prioritized are:

  • All adults 75 and older : A single dose of any licensed RSV vaccine (Arexvy, Abrysvo, or mResvia) is recommended because this age group has the highest risk of severe disease and hospitalization.
  • Adults 50–74 at higher risk : A single dose is recommended if you have conditions that raise RSV risk (for example, significant heart or lung disease, weakened immune system, or if you live in a long‑term care facility).
  • Adults 18–49 at very high risk : Some vaccines are FDA‑approved for high‑risk adults 18–49, but U.S. experts have said there is not yet enough evidence to recommend routine use in this age group; vaccination decisions are individualized.

In Short: If you are 75+ or 50–74 with notable health issues or frailty, you are squarely in the “should get RSV vaccine” group in 2025. If you are younger and generally healthy, you are usually not in a recommended group unless you have serious underlying conditions and a clinician decides the benefit is likely to outweigh risks.

Protecting infants and pregnant people

RSV is especially dangerous for very young babies, and 2024–2025 guidelines added new tools to protect them.

Key strategies in 2025:

  • Pregnant people (maternal RSV vaccine) :
    • A maternal RSV vaccine (Pfizer’s Abrysvo, also called RSVpreF) can be given during pregnancy to help the parent develop antibodies that are passed to the baby before birth.
* WHO’s 2025 position paper recommends countries use either this maternal vaccine or a monoclonal antibody (nirsevimab) to protect infants, depending on their health systems and costs.
  • Monoclonal antibody for infants (nirsevimab) :
    • This is not a “vaccine” but a long‑acting antibody shot that directly gives RSV‑fighting antibodies to the baby.
* WHO recommends it as an alternative to maternal vaccination to protect infants in their first RSV season.
  • Who is prioritized among infants (varies slightly by country, but commonly):
    • Newborns and young infants entering or born just before RSV season.
* Premature babies, infants with heart or lung disease, or certain immune problems may be given extra priority.

Bottom line for babies: In 2025, most high‑income countries aim to protect all young infants either through maternal vaccination in late pregnancy or a single monoclonal antibody dose soon after birth or before RSV season.

Who usually does not need RSV vaccine?

In 2025, RSV vaccination is not generally recommended for:

  • Healthy adults under 50 without high‑risk conditions.
  • Older children and teenagers who are otherwise healthy.
  • Most healthy middle‑aged adults (50–64) unless they have clear risk factors like chronic heart/lung disease, severe obesity, advanced diabetes, immune suppression, or residence in long‑term care.

These groups can still get RSV, but their risk of severe disease is much lower, so population‑wide vaccination would likely not provide enough benefit to justify widespread use right now.

What this means for “who should get RSV vaccine 2025”

If you are reading RSV vaccine “latest news” or forum posts in 2025, you will see a consistent theme: the shot is now part of the toolkit against winter respiratory surges, but it is targeted, not universal.

For quick self‑screening:

  1. Are you 75 or older?
    • If yes → you are clearly in a recommended group for one RSV dose.
  1. Are you 50–74 with serious heart, lung, kidney disease, diabetes with complications, immune suppression, or living in long‑term care?
    • If yes → you are also in a recommended group for one dose.
  1. Are you pregnant and due to give birth just before or during RSV season, or is your baby entering their first RSV season?
    • If yes → discuss maternal RSV vaccination or infant monoclonal antibody with your obstetric or pediatric provider.
  1. Are you younger, generally healthy, and not pregnant?
    • If yes → you are usually not in a group that is advised to get the RSV vaccine in 2025, though policies can differ outside the U.S. and are evolving.

Forum‑style note and safety reminder

“who should get rsv vaccine 2025” is a trending question because RSV vaccines and infant protections are still relatively new, and public guidance evolved between 2023 and 2025.

Because guidance varies by country and can change as new data appears, the safest move is:

  • Check your local public health website or national immunization guidelines, especially if you are outside the U.S. or Canada.
  • Bring your age, medical history, pregnancy status, and any chronic conditions to a clinician and ask directly, “Do I fall into a group that should get the RSV shot this year?”

Information gathered from public forums or data available on the internet and portrayed here.